First Maternity Unit Sales

Deltex Medical Group PLC
15 January 2007


                            Deltex Medical Group plc

      First sales of SupraQTM and CardioQTM monitors into maternity units


15 January 2007 Deltex Medical Group plc ('Deltex Medical' or the 'Company'),
the UK's leading haemodynamic monitoring company, today announces the first
sales of its SupraQ and CardioQ monitors into maternity units.

The monitors were acquired by five hospitals in London and the South-East of
England. They are to be used to develop protocols for their usage on mothers and
their babies before, during and after birth. Following an evaluation phase, a
series of randomised controlled clinical trials will be undertaken using the
devices. The project is being coordinated by the team at the Royal Free Hospital
in London which has successfully used the SupraQ as a research tool in a number
of important trials in an obstetric setting over the last four years.

The maternity applications for which the CardioQ and SupraQ monitors are being
evaluated include:

   •    caesarean sections; there are about 120,000 caesareans each year in the
        NHS in England and Wales and nearly one in six of these involve
        complications. The doctors plan to test the role of the SupraQ as a 
        routine monitor for all these patients and determine which patients 
        should have a CardioQ oesophageal probe placed and at what stage.

   •    post-operative monitoring of mothers in critical care; a small but
        significant proportion of mothers end up in critical care after giving 
        birth having suffered heavy blood loss and are likely to benefit from 
        minimally or non-invasive monitoring of their circulating blood volume.

   •    neo-natal intensive care monitoring; the CardioQ's KDP probes are
        currently labelled for use on babies of 3kg or over and this project 
        will determine the clinical need to develop the probes for use on 
        smaller (premature) babies.

   •    monitoring of mothers in labour; assessment of the SupraQ for both 
        higher risk patients (pre-eclampsia etc) and as a basic standard of care 
        (for example as an earlier indicator of risk to the baby than provided 
        by foetal heart rate monitoring).

Deltex Medical's chief executive, Andy Hill, commented:

'These contracts represent the first use of our monitoring technology in the
obstetrics market and our largest commercial sales to date of the SupraQ
monitor. The SupraQ is entirely non-invasive, ideal for use on awake patients
and allows doctors to make early interventions. We expect the SupraQ to
significantly expand the routine clinical applications of flow-based
haemodynamic monitoring.

Concluding these sales in the year just ended was an important development in
its own right. The related evaluation and research projects are a major
development as they have the potential to significantly expand over time the
existing market for the CardioQ and to establish a clearly defined market for
the entirely non-invasive SupraQ. Our approach to this new market is designed to
move as quickly as possible from proof of concept to establishing our technology
as a standard of care for a large population of patients.'


For further information, please contact:-

Deltex Medical Group plc                 01243 774 837

Nigel Keen, Chairman                     [e-mail]
Andy Hill, Chief Executive               [e-mail]
Ewan Phillips, Finance Director          [e-mail]


Gavin Anderson & Company                 0207 554 1400

Deborah Walter                           [e-mail]
Robert Speed                             [e-mail]


Charles Stanley Securities               020 7149 6457
Philip Davies                            [e-mail]


Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ, to optimise the amount of
circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-


   •    Validated the results of the Monitor against known standards for
        measuring cardiac output, demonstrating that the technology works

   •    Proved that the CardioQ works in a wide range of surgical procedures

   •    Demonstrated that the Company's technology provides significant health
        and economic benefits by helping to reduce post-operative complications 
        and length of hospital stays by an average of 30 to 40 per cent for a 
        wide range of patients.

The SupraQ is an entirely non-invasive device which uses an ultrasound probe
held at the base of the patient's neck to track the flow of blood in the aorta;
it presents the same data as the CardioQ in a similar format and is used for
taking snapshots or monitoring over short periods.



                      This information is provided by RNS
            The company news service from the London Stock Exchange